Design of inhibitors of amyloid-β misfolding and aggregation for Alzheimer's therapy

Lisbell D. Estrada, Cristian Lasagna, Claudio Soto

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations


Alzheimer's disease (AD), which afflicts an estimated 16 million people worldwide (Refolo & Fillit, 2004), is the most common cause of dementia in the elderly. By 2050, the number of people with AD is expected to triple, placing an enormous burden on the health care and social care systems. This neurodegenerative disorder is characterized clinically by progressive loss of memory, language problems, social withdrawal, and deterioration of executive functions, and eventually culminates in death (Citron, 2002). Most AD cases are sporadic, with multiple risk factors, such as aging, environmental stress, and diet. The remaining AD cases, which account for 5- 10% of total AD cases, are inherited from one generation to the next and are referred to as familial AD (FAD).

Original languageEnglish (US)
Title of host publicationPharmacological Mechanisms in Alzheimer's Therapeutics
PublisherSpringer New York
Number of pages17
ISBN (Electronic)9780387715223
ISBN (Print)9780387715216
StatePublished - Jan 1 2007



  • Alzheimer's disease
  • amyloid
  • therapy
  • β-sheet breakers

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Estrada, L. D., Lasagna, C., & Soto, C. (2007). Design of inhibitors of amyloid-β misfolding and aggregation for Alzheimer's therapy. In Pharmacological Mechanisms in Alzheimer's Therapeutics (pp. 238-254). Springer New York.